Lung Cancer | Specialty

Combination of Immunotherapy and Lung Cancer Therapies Potential Game-Changer, But Needs Further Research

August 9th 2016

Paul A. Bunn Jr, MD, discussed how combining immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy has shown promising results in recent randomized trials of patients with lung cancer, although the combinations have yet to demonstrate clear superiority.

CheckMate-026 Underscores Predictive Value of High PD-L1 Expression

August 9th 2016

The value of PD-L1 expression when using checkpoint inhibitors in non–small cell lung cancer is underscored by the just-announced disappointing progression-free survival findings from the phase III CheckMate-026 study of frontline nivolumab (Opdivo) versus physician's choice of combination chemotherapy.

Dr. West on Advancements for Patients With T790M-Mutant NSCLC

August 8th 2016

Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses recent advancements for patients with T790M-mutant non–small cell lung cancer.

Dr. Herbst on Next-Generation Agents in NSCLC

August 6th 2016

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the next generation of agents coming down the pipeline in non–small cell lung cancer.

Dr. Gandara on Recent Advancements in Field of Lung Cancer

August 6th 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.

ROS1, TRK Intriguing Targets for NSCLC

August 6th 2016

ROS1 and TRK are two emerging targets that have significant therapeutic promise for patients with non–small cell lung cancer, although they are not commonly considered while doing mutation testing.

Mok Predicts Practice-Changing Translational Advances in NSCLC

August 6th 2016

Tony Mok, MD, discussed translational advances on the horizon in non-small cell lung cancer during a presentation at the 2016 International Lung Cancer Congress.

Dr. Bunn on Missed Endpoint for Nivolumab in CheckMate-026 for NSCLC

August 5th 2016

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the phase III results from CheckMate-026, which explored nivolumab (Opdivo) monotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC

August 5th 2016

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non–small cell lung cancer.

Nivolumab Misses PFS Endpoint in Frontline Phase III NSCLC Study

August 5th 2016

Monotherapy with nivolumab failed to improve progression-free survival compared with physician's choice of combination chemotherapy for patients with PD-L1–positive non–small cell lung cancer.

Dr. Garon on Immunotherapy for Patients With NSCLC

August 5th 2016

Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.

Dr. Hirsch on Importance of Molecular Testing in Lung Cancer

August 5th 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer, discusses the importance of molecular testing for patients with lung cancer.

New Immunotherapy Classes Emerge in Lung Cancer

August 4th 2016

New classes of immunotherapies emerging in lung cancer are building on previous success with PD-1/PD-L1 inhibitors.

Pembrolizumab Gains European Approval for PD-L1+ NSCLC

August 3rd 2016

The European Commission has approved pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer following at least 1 chemotherapy regimen.

Dr. Nir Peled on Next-Generation Sequencing in Lung Cancer

August 2nd 2016

New Treatments, Greater Grasp of Biology Advance ALK+ NSCLC Care

August 1st 2016

Vamsidhar Velcheti, MD, discusses recent advancements in the ALK-positive landscape of non-small cell lung cancer, along with key questions that still remain.

Stevenson Shares Vision for Squamous NSCLC Care

July 30th 2016

James Stevenson, MD, discusses developments and ongoing research in squamous non-small cell lung cancer.

Researchers Look to Refine Use of Radiation in Oligometastatic Lung Cancer

July 29th 2016

Kevin Stephans, MD, discusses the latest research developments in oligometastases for patients with lung cancer.

Dr. El-Jawahri on Early Integrated Palliative Care in Patients With Lung or GI Cancer

July 29th 2016

Areej R. El-Jawahri, MD, assistant in Medicine, Massachusetts General Hospital, instructor in Medicine, Harvard Medical School, discusses a study examining early integrated palliative care for patients with gastrointestinal (GI) or lung cancer and the impact it has on family caregiver outcomes.

Novel Combination Study Planned for SCLC

July 25th 2016

A phase I/II study will explore the delta-like protein 3-targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T) with the PD-1 inhibitor nivolumab (Opdivo) alone or in combination with the CTLA-4 inhibitor ipilimumab (Yervoy) for patients with relapsed extensive-stage small cell lung cancer.